International Psychogeriatrics


Long-Term Use of Rivastigmine in Patients With Dementia With Lewy Bodies: An Open-Label Trial

Janet Grace a1, Sarah Daniel a1, Timothy Stevens a2, K. K. Shankar a3, Zuzanna Walker a2, E. Jane Byrne a4, Susan Butler a4, David Wilkinson a5, Jan Woolford a5, Jonathon Waite a6 and Ian G. McKeith a1
a1 Newcastle General Hospital, Newcastle upon Tyne, UK
a2 Royal Free and University College London Medical School, London, UK
a3 St. Margaret's Hospital, Essex, UK
a4 Department of Old Age Psychiatry, Withington Hospital, Manchester, UK
a5 Thornhill Research Unit, Southampton, UK
a6 University Hospital, Nottingham, UK.

Article author query
grace j   [PubMed][Google Scholar] 
daniel s   [PubMed][Google Scholar] 
stevens t   [PubMed][Google Scholar] 
shankar k   [PubMed][Google Scholar] 
walker z   [PubMed][Google Scholar] 
byrne e   [PubMed][Google Scholar] 
butler s   [PubMed][Google Scholar] 
wilkinson d   [PubMed][Google Scholar] 
woolford j   [PubMed][Google Scholar] 
waite j   [PubMed][Google Scholar] 
mckeith i   [PubMed][Google Scholar] 


Patients with dementia with lewy bodies (DLB) have progressive deficits in cognition, parkinsonism, and neuropsychiatric symptoms. Cholinesterase inhibitors have been used to ameliorate cognitive decline and neuropsychiatric symptoms in short-term trials. In this study, patients with DLB were treated with rivastigmine up to 96 weeks. Improvement from baseline was seen in cognitive function as measured by the Mini-Mental State Examination (MMSE), and neuropsychiatric symptoms as measured by the Neuropsychiatric Inventory (NPI) over the first 24 weeks of treatment. By 96 weeks, neither the MMSE scores nor the NPI scores were significantly worse than at baseline.

(Received June 22 2000)
(Accepted February 16 2001)